Idursulfase Beta
Mucopolysaccharidosis Type 2
GC Biopharma Corpprotein_peptidePhase 3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
22 Active assets in the Mucopolysaccharidosis Type 2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Idursulfase Takeda | Phase 4 | A |
PABINAFUSP ALFA JCR Pharmaceuticals Co., Ltd. | Phase 3 | BBB |
Rgx-121 REGENXBIO Inc. | Phase 3 | BB |
Rituximab Takeda | Phase 4 | BB |
METHOTREXATE Takeda | Phase 4 | BB |
View all 29 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →